Nothing Special   »   [go: up one dir, main page]

WO2006021814A3 - Medicament - Google Patents

Medicament Download PDF

Info

Publication number
WO2006021814A3
WO2006021814A3 PCT/GB2005/050108 GB2005050108W WO2006021814A3 WO 2006021814 A3 WO2006021814 A3 WO 2006021814A3 GB 2005050108 W GB2005050108 W GB 2005050108W WO 2006021814 A3 WO2006021814 A3 WO 2006021814A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
well
product
products
methods
Prior art date
Application number
PCT/GB2005/050108
Other languages
French (fr)
Other versions
WO2006021814A2 (en
Inventor
Deirdre Mcintosh
Original Assignee
Aimsco Ltd
Deirdre Mcintosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0415359.9A external-priority patent/GB0415359D0/en
Priority to US11/631,067 priority Critical patent/US20080207500A1/en
Priority to NZ552412A priority patent/NZ552412A/en
Priority to AU2005276242A priority patent/AU2005276242B2/en
Priority to CA002572777A priority patent/CA2572777A1/en
Priority to KR1020077002992A priority patent/KR101235723B1/en
Priority to JP2007519893A priority patent/JP2008505878A/en
Priority to BRPI0513062-0A priority patent/BRPI0513062A/en
Application filed by Aimsco Ltd, Deirdre Mcintosh filed Critical Aimsco Ltd
Priority to EA200700115A priority patent/EA011389B1/en
Priority to MX2007000144A priority patent/MX2007000144A/en
Priority to EP05758978A priority patent/EP1765377A2/en
Publication of WO2006021814A2 publication Critical patent/WO2006021814A2/en
Priority to IL180487A priority patent/IL180487A/en
Publication of WO2006021814A3 publication Critical patent/WO2006021814A3/en
Priority to US13/544,413 priority patent/US20130203669A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)

Abstract

Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.
PCT/GB2005/050108 2004-07-08 2005-07-08 Medicament WO2006021814A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP05758978A EP1765377A2 (en) 2004-07-08 2005-07-08 Medicament
BRPI0513062-0A BRPI0513062A (en) 2004-07-08 2005-07-08 pharmaceutical composition, method of stimulating pomc production in a patient, uses of an isolated crf peptide and an isolated pomc peptide, and methods of treating a disease, producing crf and curative, enhancer or prophylactic treatment of a disease
AU2005276242A AU2005276242B2 (en) 2004-07-08 2005-07-08 Medicament
CA002572777A CA2572777A1 (en) 2004-07-08 2005-07-08 Medicament comprising corticotropin releasing factor and proopiomelanocortin, and uses thereof
KR1020077002992A KR101235723B1 (en) 2004-07-08 2005-07-08 Medicament
JP2007519893A JP2008505878A (en) 2004-07-08 2005-07-08 Medicine
EA200700115A EA011389B1 (en) 2004-07-08 2005-07-08 Medicament
US11/631,067 US20080207500A1 (en) 2004-07-08 2005-07-08 Medicament
NZ552412A NZ552412A (en) 2004-07-08 2005-07-08 Use of corticotropin releasing factor in the treatment of neural disorders
MX2007000144A MX2007000144A (en) 2004-07-08 2005-07-08 Medicament.
IL180487A IL180487A (en) 2004-07-08 2007-01-01 Corticotropin releasing factor (crf) for treatment of neural disorders
US13/544,413 US20130203669A1 (en) 2004-07-08 2012-07-09 Medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0415359.9A GB0415359D0 (en) 2004-07-08 2004-07-08 Medicament
GB0415359.9 2004-07-08
GBGB0423386.2A GB0423386D0 (en) 2004-07-08 2004-10-21 Medicament
GB0423386.2 2004-10-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US63103708A Continuation 2004-07-08 2008-01-28

Publications (2)

Publication Number Publication Date
WO2006021814A2 WO2006021814A2 (en) 2006-03-02
WO2006021814A3 true WO2006021814A3 (en) 2007-03-29

Family

ID=35967903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/050108 WO2006021814A2 (en) 2004-07-08 2005-07-08 Medicament

Country Status (7)

Country Link
EP (1) EP1765377A2 (en)
JP (1) JP2008505878A (en)
KR (1) KR101235723B1 (en)
AU (1) AU2005276242B2 (en)
BR (1) BRPI0513062A (en)
CA (1) CA2572777A1 (en)
WO (1) WO2006021814A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415359D0 (en) * 2004-07-08 2004-08-11 Aimsco Ltd Medicament
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
GB0600202D0 (en) * 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
US7807143B2 (en) 2006-10-18 2010-10-05 Research Development Foundation Alpha-MSH therapies for treatment of autoimmune disease
WO2009040036A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100056523A (en) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 Use of grf-1 (1-29) and corticotropin-releasing factor as therapeutic agents
JP2010538980A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of angiotensin II as a therapeutic agent for Streptococcus pneumoniae infection
US20100203048A1 (en) 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer
EP2259793A2 (en) * 2008-04-30 2010-12-15 Neutron Row Use of corticotropin-releasing factor for the treatment of cancer
GB0910032D0 (en) * 2009-06-11 2009-07-22 Aimsco Ltd Use of serum composition to reduce the levels of TNF and/or VEGF in mammals
WO2011143152A2 (en) * 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
AU2013282995B2 (en) * 2012-06-25 2018-10-04 Aimsco Limited Formulation comprising CRH and alpha - 2 - immunoglobulin
WO2015033175A1 (en) * 2013-09-06 2015-03-12 Zlatko Ademovic Combination of pro-opiomelanocortin endogenous peptides in autoimmune disease treatment
GB201322948D0 (en) * 2013-12-23 2014-02-12 Aimsco Ltd Improved formulation
PL3119888T3 (en) 2014-03-19 2021-12-20 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
GB201617175D0 (en) 2016-10-10 2016-11-23 Iconic Intellectual Property Limited Assay
WO2020023737A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
GB201911064D0 (en) 2019-08-02 2019-09-18 Tarian Biologics Ltd Therapy
GB201911063D0 (en) 2019-08-02 2019-09-18 Tarian Biologics Ltd Formulations
KR102551880B1 (en) * 2020-11-13 2023-07-05 성균관대학교산학협력단 Composition for promoting the formation of neurosphere comprising Corticotropin-releasing hormone as an active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5306710A (en) * 1989-07-28 1994-04-26 Regents Of The University Of California Method for treating endotoxin shock with CRF
WO1995023214A1 (en) * 1994-02-28 1995-08-31 Ludwig Institute For Cancer Research Method for stimulating profileration of colon cells using pomc¿76-103?
WO2002067996A2 (en) * 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Beta-endorphin/crf gene therapy for locally combating pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4407489A1 (en) * 1994-03-07 1995-09-14 Bayer Ag Vaccine for the prevention of respiratory and reproductive diseases of the pig
US20030186867A1 (en) * 2000-03-31 2003-10-02 Laura Facci Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases
WO2003064472A2 (en) * 2002-01-28 2003-08-07 Aimsco Limited Treatment of ms with goat serum
MXPA04000147A (en) * 2001-07-02 2005-01-07 Aimsco Ltd Use of polyclonal anti-hiv goat serum as a therapeutic agent.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5306710A (en) * 1989-07-28 1994-04-26 Regents Of The University Of California Method for treating endotoxin shock with CRF
WO1995023214A1 (en) * 1994-02-28 1995-08-31 Ludwig Institute For Cancer Research Method for stimulating profileration of colon cells using pomc¿76-103?
WO2002067996A2 (en) * 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Beta-endorphin/crf gene therapy for locally combating pain

Also Published As

Publication number Publication date
JP2008505878A (en) 2008-02-28
AU2005276242A1 (en) 2006-03-02
KR20070042546A (en) 2007-04-23
WO2006021814A2 (en) 2006-03-02
AU2005276242B2 (en) 2011-08-25
EP1765377A2 (en) 2007-03-28
BRPI0513062A (en) 2008-04-22
CA2572777A1 (en) 2006-03-02
KR101235723B1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
WO2006021814A3 (en) Medicament
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
Sarpatwari et al. Reforming the Orphan Drug Act for the 21st century
WO2005102287A3 (en) Pharmaceutical compositions for acute glucocorticoid therapy
WO2006048449A3 (en) Mc4r selective peptides and their use in the treatment of obesity
WO2007009894A3 (en) Peptides for use in the treatment of obesity
WO2005078124A3 (en) Diagnostic marker for cancer
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2005059106A3 (en) Interferon alpha antibodies and their uses
WO2006048450A3 (en) Peptides for use in the treating obesity
IL172613A (en) Antibodies that bind at least two different human inhibitory kir gene products, hybridomas producing said antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies and use thereof for the manufacture of a medicament to potentiate nk cell activity
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2005103002A3 (en) Novel alkyne compounds with an mch-antagonistic action and medicaments comprising said compounds
WO2006035204A3 (en) Combination comprising zd6474 and an imatinib
Chang et al. Ganoderma lucidum stimulates NK cell cytotoxicity by inducing NKG2D/NCR activation and secretion of perforin and granulysin
WO2004071382A3 (en) Substituted heterocycles
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
WO2006018632A3 (en) Cell therapy with exo 1
WO2020057540A8 (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
Lee et al. Effects of magnolialide isolated from the leaves of Laurus nobilis L.(Lauraceae) on immunoglobulin E-mediated type I hypersensitivity in vitro
GB0415359D0 (en) Medicament
Ortega et al. Autophagy in Its (Proper) Context: Molecular Basis, Biological Relevance, Pharmacological Modulation, and Lifestyle Medicine
TW200510437A (en) Phosphinane compound with immunomodulating activity
Buesa et al. Iadademstat shows efficacy in elderly AML patients in combination with azacitidine. ALICE trial
DE50200711D1 (en) SUBSTANCES FOR THE THERAPY OF DISEASES CAUSED BY HIGH-POLLIFERATING CELLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005276242

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 180487

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2572777

Country of ref document: CA

Ref document number: 552412

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007519893

Country of ref document: JP

Ref document number: 12007500061

Country of ref document: PH

Ref document number: 2007/00286

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005758978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 598/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200700115

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005276242

Country of ref document: AU

Date of ref document: 20050708

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005276242

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077002992

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580028451.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005758978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11631067

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0513062

Country of ref document: BR